Pfizer's Read in Tokyo: No AZ clues but PD-L1 draws explained
This article was originally published in Scrip
If its recent potential multi-billion dollar deal for Merck KGaA's anti-PD-L1 antibody has affected Pfizer's interest in AstraZeneca as a possible takeover target, the US firm's chairman and CEO is giving nothing away.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.